Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Tri-State Area

Release Date: December 22, 2025

Expiration Date: December 22, 2026

Activity Overview

Despite growing awareness of the role of newer anti-VEGF agents in the management of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), retina specialists may still face challenges in extending patients’ treatment intervals with these agents.

Because the use of these agents may be influenced by practice infrastructure, clinician perception, and payer environment, a panel of retina specialists in the NYC Tri-State area participated in a focus group to discuss clinical hurdles they encounter in daily practice. These ranged from logistical and patient-level barriers to broader workflow or institutional constraints. In this continuing medical education program, the moderator of the focus group will provide insights into the topics, challenges, and solutions that arose during this meeting.

Target Audience

This online educational activity is directed toward ophthalmologists, optometrists, and other eye care professionals involved in the management of patients with neovascular retinal diseases.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Recognize region-specific barriers to the implementation of neovascular retinal disease management and strategies for overcoming them in clinical practice.
• Integrate advanced anti-VEGF therapies into personalized treatment plans based on local patient and workflow needs in nAMD
• Integrate advanced anti-VEGF therapies into personalized treatment plans based on local patient and workflow needs in DME
• Integrate advanced anti-VEGF therapies into personalized treatment plans based on local patient and workflow needs in RVO

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.